Purchase Order 140D0426P0102
Award Date 5/8/26
Potential Completion Date 5/7/28
Potential Value $1M
Funding Federal Agency
Contracting Federal Agency
Awardee
Ultimate Awardee
Not listed Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
- Not listed
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Bethesda, MD 20892, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Other Statutory Authority
National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The National Cancer Institute (NCI) within the National Institutes of Health (NIH) awarded a $205,376.00 firm fixed price purchase order to Illumina, Inc. for maintenance services for a government-owned Illumina NextSeq 2000 sequencing system. The base period runs from February 1, 2024 through January 31, 2028, with the potential for three one-year extensions. The contract provides for annual preventative maintenance, remote technical support, and on-site emergency repairs within two business...
- The National Cancer Institute awarded a $93,351.36 firm fixed-price purchase order to Illumina, Inc. on April 1, 2026, for a two-year maintenance agreement covering two NextSeq 2000 sequencers located at the agency's Bethesda, Maryland facility. The contract, which extends through March 31, 2027, represents a standard service and support engagement for Illumina's widely-deployed genetic sequencing instruments across the federal research enterprise. No set-aside designation was applied to this...
- The National Cancer Institute awarded a $735,959 firm fixed-price purchase order to Illumina, Inc. on March 18, 2024, for preventive maintenance and emergency repair services supporting a government-owned Illumina NovaSeq 6000 sequencing system at the National Institutes of Health Clinical Center in Bethesda, Maryland. The contract encompasses a one-year base period (March 2024 through March 2025) and includes four one-year option periods, extending through March 2029. Services include annual...
- The National Cancer Institute within the National Institutes of Health awarded a $589,617.13 firm fixed-price purchase order to Illumina, Inc. on September 1, 2021, for maintenance services supporting genomic sequencing equipment at its Bethesda, Maryland facility. The contract covers preventative maintenance and emergency support for seven Illumina sequencers and associated instrumentation used by the NCI's Genetics Branch to advance cancer research and genomic analysis capabilities. This award...
- The National Cancer Institute awarded a $256,545 firm fixed-price purchase order to Illumina, Inc. for preventive maintenance and ongoing service support of a government-owned Illumina NextSeq 2000 desktop sequencer (Serial Number: VH00760) located in San Diego, California. This contract represents Option Period Three of a multi-year maintenance agreement, with the current option period value reduced by $4,575. The contract will remain in effect through June 11, 2028, and requires qualified...
- <p>The National Cancer Institute awarded a purchase order to Illumina, Inc. valued at $60,292.06 on August 20, 2015, for service on Illumina HiSeq and two NextSeq sequencing instruments. Work is performed in Bethesda, Maryland. The order is firm fixed price with an ultimate completion date of February 19, 2016.</p>
- This firm fixed-price purchase order contract was awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Illumina, Inc. for maintenance services on a government-owned Illumina NovaSeq 6000 sequencing instrument. The $134,247.36 contract provides annual preventive maintenance, emergency repair, software/firmware updates, replacement parts, and technical support for the sequencing system located at the NCI's Laboratory of Pathology in Bethesda,...
- The National Cancer Institute (NCI) awarded a $116,652 firm fixed-price purchase order to Illumina, Inc. for preventative maintenance services on an Illumina NextSeq 550 sequencer. The contract was awarded without a set-aside and covers an initial base period from 8/21/2020 to 8/20/2021, with a total performance period through 5/7/2025. Illumina is the original equipment manufacturer (OEM) and the only known provider of these specialized maintenance services. The contract supports the NCI's...
- <p>The National Cancer Institute awarded a purchase order to Illumina, Inc. valued at $16,362.77 on February 26, 2020, for a service agreement with a firm fixed price. Work is performed in Bethesda, Maryland, with an ultimate completion date of May 31, 2020. The order procures sequencing-related services or equipment from Illumina's portfolio of genomic analysis technologies and associated support.</p>
- The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a firm fixed price purchase order contract valued at $300,280.00 to Illumina, Inc. for maintenance services on Illumina NextSeq 500 genomic sequencing equipment. The contract has a completion date of May 18, 2023 and was awarded on May 19, 2018. Illumina, a for-profit manufacturer of genomic analysis instruments and reagents, has been awarded numerous prime and subcontract federal awards...